Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow GLAUKOS Corp

Get SEC filing alerts via email and in your feed for GLAUKOS Corp

GKOS

GLAUKOS Corp

About GLAUKOS Corp

Glaukos is an ophthalmic pharmaceutical and medical device company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases. Its core products include Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release pharmaceuticals, and bio-activated therapies. Serving global markets, the company focuses on improving clinical outcomes through proprietary technologies, extensive R&D, and regulatory expertise in ophthalmology. Its business model emphasizes product development, commercialization, and strategic licensing.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from GLAUKOS Corp

1
1
GLAUKOS Corp Glaukos Corporation Reports 41% Revenue Growth to $150.6 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
GLAUKOS Corp Glaukos Corporation Reports 32% Revenue Growth to $507.4 Million in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
GLAUKOS Corp Glaukos Corporation Reports 38% Revenue Growth to $133.5 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
GLAUKOS Corp Glaukos Corporation Reports 30% Revenue Growth to $124.1 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
GLAUKOS Corp Glaukos Corporation Reports 25% Revenue Growth to $106.7 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
GLAUKOS Corp Glaukos Corporation Reports 22% Revenue Growth to $383.5 Million Despite Increased Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
GLAUKOS Corp Glaukos Corporation Reports 24% Net Sales Growth, Net Loss Reduction in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments